Merghoub T - Search Results

1

Consensus guidelines for the definition, detection and interpretation of immunogenic cell death.

Galluzzi L, Vitale I, Warren S, Adjemian S, Agostinis P, Martinez AB, Chan TA, Coukos G, Demaria S, Deutsch E, Draganov D, Edelson RL, Formenti SC, Fucikova J, Gabriele L, Gaipl US, Gameiro SR, Garg AD, Golden E, Han J, Harrington KJ, Hemminki A, Hodge JW, Hossain DMS, Illidge T, Karin M, Kaufman HL, Kepp O, Kroemer G, Lasarte JJ, Loi S, Lotze MT, Manic G, Merghoub T, Melcher AA, Mossman KL, Prosper F, Rekdal Ø, Rescigno M, Riganti C, Sistigu A, Smyth MJ, Spisek R, Stagg J, Strauss BE, Tang D, Tatsuno K, van Gool SW, Vandenabeele P, Yamazaki T, Zamarin D, Zitvogel L, Cesano A, Marincola FM. Galluzzi L, et al. Among authors: merghoub t. J Immunother Cancer. 2020 Mar;8(1):e000337. doi: 10.1136/jitc-2019-000337. J Immunother Cancer. 2020. PMID: 32209603 Free PMC article. Review.

2

The New Era of Cancer Immunotherapy: Manipulating T-Cell Activity to Overcome Malignancy.

Khalil DN, Budhu S, Gasmi B, Zappasodi R, Hirschhorn-Cymerman D, Plitt T, De Henau O, Zamarin D, Holmgaard RB, Murphy JT, Wolchok JD, Merghoub T. Khalil DN, et al. Among authors: merghoub t. Adv Cancer Res. 2015;128:1-68. doi: 10.1016/bs.acr.2015.04.010. Epub 2015 Jun 9. Adv Cancer Res. 2015. PMID: 26216629 Review.

3

Tumor-Expressed IDO Recruits and Activates MDSCs in a Treg-Dependent Manner.

Holmgaard RB, Zamarin D, Li Y, Gasmi B, Munn DH, Allison JP, Merghoub T, Wolchok JD. Holmgaard RB, et al. Among authors: merghoub t. Cell Rep. 2015 Oct 13;13(2):412-24. doi: 10.1016/j.celrep.2015.08.077. Epub 2015 Sep 24. Cell Rep. 2015. PMID: 26411680 Free PMC article.

4

Genetics and immunology: reinvigorated.

Snyder A, Makarov V, Hellmann M, Rizvi N, Merghoub T, Wolchok JD, Chan TA. Snyder A, et al. Among authors: merghoub t. Oncoimmunology. 2015 Apr 14;4(10):e1029705. doi: 10.1080/2162402X.2015.1029705. eCollection 2015 Oct. Oncoimmunology. 2015. PMID: 26451299 Free PMC article.

5

Targeting myeloid-derived suppressor cells with colony stimulating factor-1 receptor blockade can reverse immune resistance to immunotherapy in indoleamine 2,3-dioxygenase-expressing tumors.

Holmgaard RB, Zamarin D, Lesokhin A, Merghoub T, Wolchok JD. Holmgaard RB, et al. Among authors: merghoub t. EBioMedicine. 2016 Apr;6:50-58. doi: 10.1016/j.ebiom.2016.02.024. Epub 2016 Feb 13. EBioMedicine. 2016. PMID: 27211548 Free PMC article.

6

Intratumoral modulation of the inducible co-stimulator ICOS by recombinant oncolytic virus promotes systemic anti-tumour immunity.

Zamarin D, Holmgaard RB, Ricca J, Plitt T, Palese P, Sharma P, Merghoub T, Wolchok JD, Allison JP. Zamarin D, et al. Among authors: merghoub t. Nat Commun. 2017 Feb 13;8:14340. doi: 10.1038/ncomms14340. Nat Commun. 2017. PMID: 28194010 Free PMC article.

7

Intratumoral delivery of inactivated modified vaccinia virus Ankara (iMVA) induces systemic antitumor immunity via STING and Batf3-dependent dendritic cells.

Dai P, Wang W, Yang N, Serna-Tamayo C, Ricca JM, Zamarin D, Shuman S, Merghoub T, Wolchok JD, Deng L. Dai P, et al. Among authors: merghoub t. Sci Immunol. 2017 May 19;2(11):eaal1713. doi: 10.1126/sciimmunol.aal1713. Sci Immunol. 2017. PMID: 28763795 Free PMC article.

8

A neoantigen fitness model predicts tumour response to checkpoint blockade immunotherapy.

Łuksza M, Riaz N, Makarov V, Balachandran VP, Hellmann MD, Solovyov A, Rizvi NA, Merghoub T, Levine AJ, Chan TA, Wolchok JD, Greenbaum BD. Łuksza M, et al. Among authors: merghoub t. Nature. 2017 Nov 23;551(7681):517-520. doi: 10.1038/nature24473. Epub 2017 Nov 8. Nature. 2017. PMID: 29132144 Free PMC article.

9

Immune-Active Microenvironment in Small Cell Carcinoma of the Ovary, Hypercalcemic Type: Rationale for Immune Checkpoint Blockade.

Jelinic P, Ricca J, Van Oudenhove E, Olvera N, Merghoub T, Levine DA, Zamarin D. Jelinic P, et al. Among authors: merghoub t. J Natl Cancer Inst. 2018 Jul 1;110(7):787-790. doi: 10.1093/jnci/djx277. J Natl Cancer Inst. 2018. PMID: 29365144 Free PMC article.

10

Pre-existing Immunity to Oncolytic Virus Potentiates Its Immunotherapeutic Efficacy.

Ricca JM, Oseledchyk A, Walther T, Liu C, Mangarin L, Merghoub T, Wolchok JD, Zamarin D. Ricca JM, et al. Among authors: merghoub t. Mol Ther. 2018 Apr 4;26(4):1008-1019. doi: 10.1016/j.ymthe.2018.01.019. Epub 2018 Jan 31. Mol Ther. 2018. PMID: 29478729 Free PMC article.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

200 results

Search Page